Trimetazidine effects on oxidative damage
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, S.J. | - |
dc.date.accessioned | 2021-12-29T06:28:49Z | - |
dc.date.available | 2021-12-29T06:28:49Z | - |
dc.date.created | 2021-08-31 | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1566-0338 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/133569 | - |
dc.description.abstract | Trimetazidine is an anti anginal medication and ensures the proper functioning of transmembrane ionic channels by maintaining intracellular ATP production in ischemic conditions. Trimetazidine prevents the accumulation of calcium in cardiomyocytes, adjusts cellular acidosis, and decreases production of free oxygen radicals. Trimetazidine blocks long chain 3-ketoacyl coenzyme A thiolase activity, thereby shifting ATP production more towards glucose oxidation instead of fatty acid β-oxidation during myocardial ischemia. By inhibiting fatty acid β-oxidation, fewer free radicals are formed in the cardiomyocytes with more efficient oxygen consumption and ATP production, resulting in recovery of myocardial contractile function and inhibition of malignant arrhythmias. Moreover, cardiac enzymatic activities such as phosphorylase and ATPase increased significantly in ischemic areas with trimetazidine pretreatment before myocardial ischemia. Protective effects of trimetazidine by increasing ventricular fibrillation threshold during coronary artery occlusion were consistent in animal studies. © 2013 by ISSN. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.subject | acetyl coenzyme A acyltransferase | - |
dc.subject | trimetazidine | - |
dc.subject | article | - |
dc.subject | drug mechanism | - |
dc.subject | fatty acid oxidation | - |
dc.subject | glucose oxidation | - |
dc.subject | heart muscle ischemia | - |
dc.subject | heart protection | - |
dc.subject | heart ventricle fibrillation | - |
dc.subject | human | - |
dc.subject | ischemic heart disease | - |
dc.subject | nonhuman | - |
dc.subject | oxidative stress | - |
dc.subject | priority journal | - |
dc.title | Trimetazidine effects on oxidative damage | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hong, S.J. | - |
dc.identifier.scopusid | 2-s2.0-84891953210 | - |
dc.identifier.bibliographicCitation | Heart and Metabolism, no.60, pp.27 - 29 | - |
dc.relation.isPartOf | Heart and Metabolism | - |
dc.citation.title | Heart and Metabolism | - |
dc.citation.number | 60 | - |
dc.citation.startPage | 27 | - |
dc.citation.endPage | 29 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | acetyl coenzyme A acyltransferase | - |
dc.subject.keywordPlus | trimetazidine | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | drug mechanism | - |
dc.subject.keywordPlus | fatty acid oxidation | - |
dc.subject.keywordPlus | glucose oxidation | - |
dc.subject.keywordPlus | heart muscle ischemia | - |
dc.subject.keywordPlus | heart protection | - |
dc.subject.keywordPlus | heart ventricle fibrillation | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | ischemic heart disease | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | oxidative stress | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordAuthor | Myocardial infarction | - |
dc.subject.keywordAuthor | Oxidative damage | - |
dc.subject.keywordAuthor | Trimetazidine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.